• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Investigation of a Putative Estrogen-Imprinting Gene, Phosphodiesterase Type IV Variant (PDE4D4), in Determining Prostate Cancer Risk
【24h】

Investigation of a Putative Estrogen-Imprinting Gene, Phosphodiesterase Type IV Variant (PDE4D4), in Determining Prostate Cancer Risk

机译：推定雌激素印迹基因，磷酸二酯酶IV型变异体（pDE4D4）在确定前列腺癌风险中的研究

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Estrogens are known to play a role in the initiation and progression of prostate cancer. Recently environmental factors such as xenoestrogens have been reported on their prevalence of prostate diseases or cancers. Estrogen imprinting of the prostate gland is believed to associate with an increased incidence of prostatic lesions including inflammation epithelial hyperplasia squamous metaplasia dysplasia and adenocarcinoma. And DNA methylation may be one of the possible mechanisms of the prostate reprogramming. By using one of the global methylation profiling techniques MSRF a gene called phosphodiesterase type IV variant 4 (PDE4D4) was shown to be hypomethylated following neonatal exposure to estradiol (EB) or bisphenol A (BPA). We further confirmed the persistence of PDE4D4 promoter hypomethylation and gene up- regulation in the adult life by using bisulfite genomic sequencing and real- time PCR. PDE4D4 has function of cAMP-degradation to maintain the second messenger cAMP in a narrow range of concentrations that is critical for growth and differentiation of the hormone target cells by activating several downstream signaling molecules. Taken together these findings supported that PDE4D4 dysregulation via CpG island hypomethylation at its promoter regions in early life by EB or BPA can alter its expression and activity of the gene. Present data also suggested that PDE4D4 can be used as a biomarker for prostate cancer assessment.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号